skip to content
Propranolol hydrochloride (Hemangiol). Preview this item
ClosePreview this item
Checking...

Propranolol hydrochloride (Hemangiol).

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
Infantile hemangiomas (IHs) are the most common vascular tumours occurring in children. The incidence and prevalence of IH in Canada is uncertain; however, the manufacturer has estimated that the incidence of IH ranges from 4.5% to 10.0%. Hemangiol is an oral solution containing 3.75 mg/mL propranolol that is indicated for the treatment of proliferating IH requiring systemic therapy in the following circumstances:  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Review
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1043426470
Description: 1 online resource (1 PDF file (ix, 55 pages) : illustrations.
Series Title: Common drug review clinical review report.

Abstract:

Infantile hemangiomas (IHs) are the most common vascular tumours occurring in children. The incidence and prevalence of IH in Canada is uncertain; however, the manufacturer has estimated that the incidence of IH ranges from 4.5% to 10.0%. Hemangiol is an oral solution containing 3.75 mg/mL propranolol that is indicated for the treatment of proliferating IH requiring systemic therapy in the following circumstances: life- or function-threatening hemangioma; ulcerated hemangioma with pain and/or lack of response to simple wound care measures; or hemangioma with a risk of permanent scarring or disfigurement. The manufacturer has requested that propranolol oral solution receive a recommendation to reimburse in accordance with the Health Canada-approved indication. Propranolol oral solution is the first treatment specifically indicated for the treatment of patients with IH in Canada. The product monograph states that treatment should be initiated in infants aged five weeks to five months and the age for treatment initiation should be corrected in cases of premature birth. The recommended therapeutic dosage of propranolol for the treatment of IH is 3 mg/kg/day (administered as 1.5 mg/kg twice daily). The product monograph recommends that the first dose and each dose escalation should be administered in a clinical setting where there are adequate facilities for handling adverse events, including events that require urgent measures. The CADTH Common Drug Review (CDR) conducted a systematic review to evaluate the beneficial and harmful effects of propranolol oral solution for the treatment of proliferating IH requiring systemic therapy. The CDR review focused on the use of propranolol at the Health Canada-approved dosage regimen of 3 mg/kg/day for six months.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1043426470> # Propranolol hydrochloride (Hemangiol).
    a schema:CreativeWork, schema:Book, schema:MediaObject ;
    library:oclcnum "1043426470" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/5314375378#Topic/propranolol_adverse_effects> ; # Propranolol--adverse effects
    schema:about <http://experiment.worldcat.org/entity/work/data/5314375378#Topic/adrenergic_beta_antagonists> ; # Adrenergic beta-Antagonists
    schema:about <http://experiment.worldcat.org/entity/work/data/5314375378#Topic/infant> ; # Infant
    schema:about <http://experiment.worldcat.org/entity/work/data/5314375378#Topic/propranolol_therapeutic_use> ; # Propranolol--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/5314375378#Topic/hemangioma_drug_therapy> ; # Hemangioma--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/5314375378#Topic/child> ; # Child
    schema:about <http://experiment.worldcat.org/entity/work/data/5314375378#Topic/treatment_outcome> ; # Treatment Outcome
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/5314375378#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2017" ;
    schema:description "Infantile hemangiomas (IHs) are the most common vascular tumours occurring in children. The incidence and prevalence of IH in Canada is uncertain; however, the manufacturer has estimated that the incidence of IH ranges from 4.5% to 10.0%. Hemangiol is an oral solution containing 3.75 mg/mL propranolol that is indicated for the treatment of proliferating IH requiring systemic therapy in the following circumstances: life- or function-threatening hemangioma; ulcerated hemangioma with pain and/or lack of response to simple wound care measures; or hemangioma with a risk of permanent scarring or disfigurement. The manufacturer has requested that propranolol oral solution receive a recommendation to reimburse in accordance with the Health Canada-approved indication. Propranolol oral solution is the first treatment specifically indicated for the treatment of patients with IH in Canada. The product monograph states that treatment should be initiated in infants aged five weeks to five months and the age for treatment initiation should be corrected in cases of premature birth. The recommended therapeutic dosage of propranolol for the treatment of IH is 3 mg/kg/day (administered as 1.5 mg/kg twice daily). The product monograph recommends that the first dose and each dose escalation should be administered in a clinical setting where there are adequate facilities for handling adverse events, including events that require urgent measures. The CADTH Common Drug Review (CDR) conducted a systematic review to evaluate the beneficial and harmful effects of propranolol oral solution for the treatment of proliferating IH requiring systemic therapy. The CDR review focused on the use of propranolol at the Health Canada-approved dosage regimen of 3 mg/kg/day for six months."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/5314375378> ;
    schema:genre "Review"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/5314375378#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/5314375378#Series/common_drug_review> ; # Common drug review
    schema:name "Propranolol hydrochloride (Hemangiol)."@en ;
    schema:productID "1043426470" ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK476392> ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK476392/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1043426470> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/5314375378#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/5314375378#Series/common_drug_review> # Common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1043426470> ; # Propranolol hydrochloride (Hemangiol).
    schema:name "Common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/5314375378#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1043426470> ; # Propranolol hydrochloride (Hemangiol).
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/5314375378#Topic/adrenergic_beta_antagonists> # Adrenergic beta-Antagonists
    a schema:Intangible ;
    schema:name "Adrenergic beta-Antagonists"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5314375378#Topic/hemangioma_drug_therapy> # Hemangioma--drug therapy
    a schema:Intangible ;
    schema:name "Hemangioma--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5314375378#Topic/propranolol_adverse_effects> # Propranolol--adverse effects
    a schema:Intangible ;
    schema:name "Propranolol--adverse effects"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5314375378#Topic/propranolol_therapeutic_use> # Propranolol--therapeutic use
    a schema:Intangible ;
    schema:name "Propranolol--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5314375378#Topic/treatment_outcome> # Treatment Outcome
    a schema:Intangible ;
    schema:name "Treatment Outcome"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.